Streetbeat News

Products Services

SDGR

Schrödinger, a company that develops chemical simulation software for pharmaceutical and biotechnology research, has announced an expanded three-year software agreement with illy, a renowned coffee company. The agreement will allow illy to utilize Schrödinger's software to enhance its coffee products. This collaboration signifies a unique application of Schrödinger's technology outside its typical pharmaceutical domain, potentially opening new market opportunities for the company.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:34 pm

REGN

Medison Pharma has entered into an agreement with Regeneron Pharmaceuticals to commercialize Libtayo, a cancer treatment drug, in multiple countries. This partnership could potentially expand the market reach of Libtayo and enhance its sales, benefiting Regeneron's revenue stream and market presence in the oncology sector.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:32 pm

SNGX

Soligenix announced that its SGX945 (dusquetide) development program for the treatment of oral lesions in Behçet's Disease has been granted 'Fast Track' designation by the FDA. This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:32 pm

VVOS

Vivos Therapeutics reports a 600% increase in new dentist inquiries to participate in its Integrated Practice program and a 38% rise in signed dentist enrollment contracts over Q3.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:31 pm

BLCO

Bausch + Lomb, a global eye health company, has announced that the FDA has approved its TENEO Excimer Laser Platform for use in LASIK surgery for myopia and myopic astigmatism. This approval could enhance the company's product offerings in the vision correction surgery market.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:31 pm

MRKR

Marker Therapeutics announced a strategic prioritization of its clinical programs, emphasizing the development of MT-601 for patients with lymphoma. This decision indicates a refocusing of the company's resources and efforts on advancing this particular treatment, which may have implications for its pipeline and financial allocations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:30 pm

MRKR

Marker Therapeutics provided updates on its clinical programs and pipeline prioritization, focusing on advancing multiple product candidates. The company is prioritizing its resources to accelerate the development of its most promising therapies. Specific updates on clinical trials or regulatory milestones were not provided in the news.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:29 pm

PLUR

Pluri has announced the launch of PluriCDMO, a new business division focused on providing cell therapy manufacturing services. This move positions Pluri as a Contract Development and Manufacturing Organization (CDMO) within the $5.2 billion cell and gene therapy market. The new division aims to assist companies in developing and manufacturing transformative cell therapies.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:28 pm

GLUE

Monte Rosa Therapeutics (NASDAQ:GLUE) announced its cash position is expected to fund operations into the first half of 2026. The company will present at the 42nd Annual J.P. Morgan Healthcare Conference, focusing on 2024 strategic priorities, including the Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors and development plans for MRT-2359 and MRT-6160. MRT-2359 has received US FDA Fast Track Designation for small cell lung cancer and the recommended Phase 2 dose is expected in Q2 2024. MRT-6160 is anticipated to begin Phase 1 study in mid-2024 for autoimmune diseases.

Portfolio Pulse from Charles Gross

January 08, 2024 | 12:27 pm

BA

HELE

QQQ

SPR

SPY

Dow futures indicate a lower market opening, influenced by Boeing's (NYSE:BA) 737 MAX 9 jets grounding after an accident, affecting airline stocks. Traders are cautious ahead of inflation reports and bank earnings. U.S. stocks retreated last week, with tech and small-cap stocks dragging indices down after a nine-week rally. Analysts predict volatility but suggest solid fundamentals may limit damage. SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ ETF (NASDAQ:QQQ) saw slight premarket declines. Boeing shares dropped over 8%, and Spirit AeroSystems Holdings, Inc. (NYSE:SPR) fell nearly 20% due to its connection to the Boeing incident. Helen of Troy Limited (NASDAQ:HELE) is set to release earnings. Oil prices recoiled, and Bitcoin (CRYPTO:BTC) remained positive.

Portfolio Pulse from Shanthi Rexaline

January 08, 2024 | 12:26 pm